FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to polypeptide compounds, which are modulators (such as agonists and antagonists) of melanocortin-4 receptor (MC4R), as well as to pharmaceutical compositions containing such compounds. Compounds described herein are polypeptides of structural formula (I) or pharmaceutically acceptable salts thereof. Values and preferred values of variables present in structural formula (I) are defined in the claim.
.
EFFECT: polypeptides can be used for treating disorders sensitive to modulation of MC4R, where the disorder is type 1 diabetes, type 2 diabetes, obesity, insulin resistance, metabolic syndrome, male erectile dysfunction, female sexual dysfunction, non-alcoholic fatty liver dystrophy or non-alcoholic steatohepatitis.
14 cl, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS | 2014 |
|
RU2690377C2 |
| METHOD FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCORTIN 4 RECEPTOR PATH | 2016 |
|
RU2785889C1 |
| HYDANTOIN MODIFIED MELANOCORTIN RECEPTOR LIGANDS | 2008 |
|
RU2450017C2 |
| MELANOCORTIN RECEPTOR LIGANDS | 2006 |
|
RU2380372C2 |
| MELANOCORTIN RECEPTOR LIGANDS | 2006 |
|
RU2439079C2 |
| ANALOGUES OF PEPTIDE LH-RF, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | 1998 |
|
RU2212247C2 |
| PRODRUG COMPOSITIONS WITH HIGH DEGREE OF PENETRATION BASED ON PEPTIDES AND RELATED COMPOUNDS | 2010 |
|
RU2627065C2 |
| PEPTIDE VECTORS | 2004 |
|
RU2361876C2 |
| NEUROMEDIN AND SOMATOSTATIN RECEPTOR AGONISTS | 2000 |
|
RU2263680C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
